灯盏生脉胶囊干预急性进展性脑梗死的前瞻性研究  

Prospective study on treatment of acute progressive cerebral infarction with Dengzhan Shengmai capsule

作　　者：毛德军[1] 宫相聪 唐咏春[1] 郭瑞友[1] 

机构地区：[1]青岛大学医学院附属海慈医疗集团神经内科,青岛266033 [2]青岛市即墨兰村中心卫生院内科,即墨266232

出　　处：《中国新药杂志》2010年第11期959-962,共4页Chinese Journal of New Drugs

摘　　要：目的:探讨灯盏生脉胶囊对急性进展性脑梗死(acute progressive cerebral infarction,APCI)的干预作用及外周血单个核细胞(peripheral blood mononuclear cells,PBMC)趋化因子受体1(CX3C-chemokine re-ceptor 1,CX3CR1)、锌指蛋白A20表达的变化。方法:将起病7 d以内的100例APCI患者分为对照组和试验组,每组各50例患者,所有病例均采用常规治疗,试验组除常规治疗外还给予灯盏生脉胶囊治疗。分别于入院时、病程d7,d14和d30检测两组患者Scandinavian卒中量表评分(Scandinavian stroke scale,SSS)、PB-MC CX3CR1及锌指蛋白A20表达的变化;于入院时、病程d 30检测两组患者梗死灶体积。结果:对照组病程d7,d14及d30 SSS均明显低于试验组(P<0.05);试验组病程d 30梗死灶体积及病程d 7,d 14及d30PBMC CX3CR1的表达均明显低于对照组(P<0.05)。结论:灯盏生脉胶囊可通过下调PBMC CX3CR1的表达而改善其预后。Objective： To determine the effect of Dengzhan Shengmai capsule on acute progressive cerebral infarction（APCI）,and the changes of CX3CR1 and the zinc finger protein A20 in peripheral blood mononuclear cells（PBMC）.Methods： One hundred patients with APCI,less than 7 d of the onset,were divided into 2 groups（n=50 for each group）.They were treated with routine therapy alone（control） or combined with Dengzhan Shengmai capsule.The changes in Scandinavian Stroke Scale（SSS） were evaluated,and the expression of CX3CR1 and zinc finger protein A20 in PBMC were measured on admission and 7,14,30 days after admission.The infarction volume was measured on admission and 30 days after admission.Results： SSS at 7,14 and 30 days was obviously lower in control group than in Dengzhan Shengmai capsule group（P0.05）.The infarction volume at 30 days was smaller,and the expression of CX3CR1 in PBMC was lower in Dengzhan Shengmai capsule group than in control group（P0.05）.Conclusion： Dengzhan Shengmai capsule can improve the prognosis of patients with APCI by reducing CX3CR1 expression in PBMC.

关 键 词：灯盏生脉胶囊 脑梗死 趋化因子受体1 锌指蛋白A20 核磁共振成像 

分 类 号：R743.3[医药卫生—神经病学与精神病学]